Related references
Note: Only part of the references are listed.Effectiveness of allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia
Frederick R. Appelbaum
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2021)
Can venetoclax-based therapy replace 7+3 induction in fit older adults with AML?
James M. Foran
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2021)
Evolving Therapeutic Approaches for Older Patients with Acute Myeloid Leukemia in 2021
Irene Urbino et al.
CANCERS (2021)
CPX-351: an attractive option for the treatment of older patients with high-risk or secondary acute myeloid leukaemia
Xavier Thomas et al.
Lancet Haematology (2021)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial
Maria Teresa Voso et al.
BLOOD ADVANCES (2020)
Cancer treatment and survivorship statistics, 2019
Kimberly D. Miller et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD
Richard F. Schlenk et al.
BLOOD (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Jorge E. Cortes et al.
LEUKEMIA (2019)
Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA plus )
Jose Falantes et al.
LEUKEMIA & LYMPHOMA (2018)
Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
Hartmut Doehner et al.
LEUKEMIA (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia
Pierre-Yves Dumas et al.
ONCOTARGET (2017)
Impact of allogeneic hematopoietic cell transplantation on the outcome of older patients with acute myeloid leukemia
Frederick R. Appelbaum
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2017)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein et al.
BLOOD (2017)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Herve Dombret et al.
BLOOD (2015)
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction
F. Ramos et al.
LEUKEMIA RESEARCH (2015)
Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group
Lisa Pleyer et al.
ANNALS OF HEMATOLOGY (2014)
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
Robert K. Hills et al.
LANCET ONCOLOGY (2014)
Acute myeloid leukemia in the real world: why population-based registries are needed
Gunnar Juliusson et al.
BLOOD (2012)
Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age 60-70 Years with Acute Myelogenous Leukemia in First Remission
Sherif S. Farag et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
Hagop Kantarjian et al.
BLOOD (2010)
Acute Myeloid Leukemia With Translocation (8;21) or Inversion (16) in Elderly Patients Treated With Conventional Chemotherapy: A Collaborative Study of the French CBF-AML Intergroup
Thomas Prebet et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment
Alan K. Burnett et al.
CANCER (2007)
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
ML Sorror et al.
BLOOD (2005)
Share Paper
